Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

NCT02250443 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Sporadic Inclusion Body Myositis (sIBM)

Interventions

DRUG: BYM338 (Bimagrumab)

Sponsor

Novartis Pharmaceuticals